/ MRK
/ Earnings
Merck & Co. Beats Expectations in Q3 2025, Lifts Full-Year Forecast
Merck reported Q3 2025 revenue of $17.3 billion and adjusted EPS of $2.58, both above expectations, and raised its full-year outlook.
October 30, 2025
Merck & Co., Inc. Reports Mixed Second-Quarter 2025 Results
Merck's second-quarter performance showed a slight decline in sales compared to the previous year.
July 29, 2025
Merck & Co. (MRK) Reports Better than Expected Results for First-Quarter 2025
Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments.
April 24, 2025
Merk’s Stock Dips as Trump Tariff Plans Now Threaten Pharma Trade
President Trump's proposed tariffs on imported pharmaceuticals could significantly impact global trade.
April 09, 2025
Merck’s Stock Rises Amid New Cancer Treatment Drug Breakthrough
MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving treatment time.
March 28, 2025More from The Tokenist / MRK
Merck Reports Mixed Q4: Beats Revenue, Short on EPS Expectations
February 04, 2025
Back to 
